Breaking News on Supplements & Nutrition - EuropeUS edition

On your radar > Probiotics

Loading...

New models hold promise for probiotic claim substantiation

By Nathan Gray+

29-Nov-2012

Exposing healthy people to modified pathogens in a controlled clinical trial setting could be an exciting new way for industry to overcome the challenges of health claim substantiation, says Nizo Food Research expert.

Probiotics have been a hot topic of late, with attempts to gain EFSA approved health claims causing a number of headaches for the sector.

However, Alwine Kardinaal, senior researcher for health and nutrition at Nizo Food Research believes new challenge models that expose healthy participants to modified versions of pathogens show great promise in elucidating the positive health effects of probiotics.

“EFSA does not accept that there are good or bad bacteria, but they do accept that claims should focus on resistance against pathogens,” explained Kardinaal. “The problem is that there are not very good markers for this.”  

“What is necessary to substantiate a claim in this area is to look at clinical symptoms caused by pathogens, and that is not an easy answer.”

“you need people to get infected”

Kardinaal said that one of the key challenges for industry is that they need to be able to show a positive effect in the target population for the product that will bear the claim – healthy people.

“That means that you need people to get infected,” she said. “There are a number of models that you can think of to do the trick.”

The Nizo expert said while models of spontaneous infection can work, in which people who may be more likely to become ill often are studied, there is an issue with the spontaneous nature of the infections that may occur.

“The problem with such studies is that you don’t know upfront who is going to get infected and who is not. So these typse of studies require quite a large number of study participants which makes them relatively expensive and complex.

A potential solution to this, she noted, is to perform what is essentially a randomised clinical trial by exposing healthy individuals to a pathogen in a controlled way.

“That is a model that we have used in a number of situations,” said Kardinaal. “It can be used to show effects on resistance against pathogens of probiotics, prebiotics, but other ingredients as well.”

Related products

Building for the future: DSM on lessons from Food Vision 2014

Building for the future: DSM on lessons from Food Vision 2014

Industry needs to ‘dramatically innovate’ if it is to come up with sustainable solutions...

Food Vision 2014: Bridge knowledge gaps, overcome change and work sustainably

Food Vision 2014: Bridge knowledge gaps, overcome change and work sustainably

What is the future of food? Simple communication of complex advances will be crucial,...

Innovation for today: Digital tech empowers industry to innovate

Innovation for today: Digital tech empowers industry to innovate

Chris Cornyn

founder & president, DINE Marketing

Global probiotic market to add 50% to €33bn by 2018: Analyst

Global probiotic market to add 50% to €33bn by 2018: Analyst

Ewa Hudson

Global head of health and wellness research , Euromonitor International

Festive video insights: Mintel experts offer up highlights and predictions

Festive video insights: Mintel experts offer up highlights and predictions

With 2013 fast drawing to a close and 2014 just around the corner, we...

'Mood foods' are on the rise, says Mintel

'Mood foods' are on the rise, says Mintel

Laura Jones

Global food science analyst, Mintel

The European food industry: Health claims, recession and global competition

The European food industry: Health claims, recession and global competition

We gave the European food industry a check-up at this year’s Food Ingredients Europe...

Leatherhead’s top 3 new products at FiE

Leatherhead’s top 3 new products at FiE

Steve Osborn

Business Innovation Manager , Leatherhead Food Research

Protein has a big ‘ordinary’ future, says Glanbia

Protein has a big ‘ordinary’ future, says Glanbia

Carla Clissman

European commercial director, , Glanbia Nutritionals

High-protein bread could bake up a storm: Euromonitor

High-protein bread could bake up a storm: Euromonitor

Diana Cowland

Senior Analyst, Health & Wellness, Euromonitor International

Cutting carbs, gluten or fat? The 'utter nonsense' behind claims to be the best diet

Cutting carbs, gluten or fat? The 'utter nonsense' behind claims to be the best diet

Dr David Katz

ddirector of Prevention Research Center. , Yale University

‘Functional beverage belief is back’: Zenith International chair

‘Functional beverage belief is back’: Zenith International chair

Zenith International chairman Richard Hall tells BeverageDaily.com that he thinks the beverage industry is...

Algatech: Functional food on astaxanthin horizon

Algatech: Functional food on astaxanthin horizon

Israeli firm Algatechnologies will work towards gaining approval for its astaxanthin as a novel...

Industry must debunk whey protein bodybuilding myths: Volac

Industry must debunk whey protein bodybuilding myths: Volac

Michael Hiron

Commercial Manager, Lifestyle Nutrition, Volac

Fed up: Probiotic research veteran issues global call to action

Fed up: Probiotic research veteran issues global call to action

Veteran probiotic researcher professor Gregor Reid is not a happy man. It’s time the...

Arsenal FC nutritionist: ‘Food supplements have a big part to play.’

Arsenal FC nutritionist: ‘Food supplements have a big part to play.’

James Collins

Sport and exercise nutritionist, Arsenal Football Club

FIE 2013: FoodNavigator team round-up

FIE 2013: FoodNavigator team round-up

Our team of journalists is back in the office after three very busy days...

Key Industry Events